RT Journal Article
T1 Working with companies that manufacture breastmilk substitutes: An EAACI position paper
A1 Arasi, Stefania
A1 Caubet, J.C.
A1 Ceylan, Ozlem
A1 Ibon Eguíluz, Gracia
A1 Giacco, Stefano Del
A1 Gelincik, Asli
A1 Jute, Marek
A1 Rosan, Meyer
A1 Ollert, Markus
A1 Torres-Jaén, María Josefa
K1 Leche materna
K1 Alergia
AB Breastmilk is the optimal source of nutrition for infants and should ideally be provided exclusively for the first 6 months of life, and alongside complementary food until 2 years of life. However, there are circumstances where a breastmilk substitute (BMS) may be required. This includes maternal and/or child conditions or personal preference. Whilst these circumstances should never be used as an opportunity to promote BMS, healthcare professionals (HCPs) need to have the knowledge of suitable alternatives and should always be guided by scientific and health motives when recommending a BMS. The Task Force ‘Milk Formula Industry Sponsorship’ from the European Academy of Allergy and Clinical Immunology (EAACI), provides with this publication recommendations for EAACI interactions with the BMS manufacturers and how this will be supervised.
PB Wiley
YR 2024
FD 2024-05
LK https://hdl.handle.net/10630/31762
UL https://hdl.handle.net/10630/31762
LA eng
NO Arasi S, Caubet J-C, Ceylan O, et al. Working with companies that manufacture breastmilk substitutes: An EAACI position paper. Pediatr Allergy Immunol. 2024; 0:e14142.
NO Funding for open access charge: Universidad de Málaga/CBUA
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 20 ene 2026